In a patient with moderate-to-severe rheumatoid arthritis inadequately controlled by conventional disease-modifying antirheumatic drugs, when should upadacitinib be preferred over tofacitinib, and vice versa?

Upadacitinib vs Tofacitinib for Rheumatoid Arthritis

Upadacitinib 15 mg once daily should be preferred over tofacitinib 5 mg twice daily in patients with moderate-to-severe rheumatoid arthritis inadequately controlled by conventional DMARDs, based on superior efficacy in achieving clinical remission and ACR responses. 1, 2

Efficacy Comparison

Clinical Response Rates

Upadacitinib demonstrates numerically superior efficacy across multiple endpoints:

• ACR50 at 3 months: Upadacitinib + MTX achieved 12.9% higher response rates compared to tofacitinib + MTX (p=0.011) 1
• Clinical Remission at 6 months: Upadacitinib + MTX showed significantly greater remission rates:
  • SDAI remission: 9.1% higher (p=0.011)
  • CDAI remission: 7.5% higher (p=0.038)
  • DAS28-ESR remission: 11.3% higher (p=0.002) 1

Network meta-analysis confirms upadacitinib 15 mg + csDMARD had the highest probability of being the best treatment (SUCRA = 0.820 for ACR20), followed by tofacitinib 5 mg (SUCRA = 0.424) 2

Speed of Response

Upadacitinib produces faster clinical improvement, with ultrasound studies showing lower echography scores achieved more rapidly than tofacitinib, though differences equalize by weeks 12-24 3. This translates to earlier symptom relief for patients.

Monotherapy Performance

When used as monotherapy, upadacitinib achieved higher ACR50 response (38.5%) compared to tofacitinib (30.4%), with the added benefit of superior ACR70 response (9.9% higher, p=0.019) at 3 months 1, 2

Safety Considerations

Age and Cardiovascular Risk

Critical caveat: In patients ≥65 years with cardiovascular risk factors or history of heavy smoking, the 2026 PANLAR guidelines conditionally recommend JAK inhibitors only after csDMARD or bDMARD failure, and when biologics are contraindicated or unavailable 4. This applies to both agents but is particularly relevant given:

• Tofacitinib 10 mg twice daily showed increased serious infection rates in elderly patients compared to TNF inhibitors 5
• The 5 mg twice daily dose had similar infection risk to adalimumab in younger patients, but several-fold higher risk at 10 mg twice daily in elderly 5

Infection Risk

Both agents carry comparable serious infection rates to adalimumab at approved doses 5. No clinically meaningful safety differences were detected in real-world 2-year observational data 6.

Drug Interactions

Tofacitinib requires more dose adjustments:

• Rifampicin (TB prophylaxis): Increases metabolism of both tofacitinib and upadacitinib, requiring dose increase consideration 5
• Ketoconazole: Inhibits metabolism, requiring dose reduction 5
• Renal impairment: Tofacitinib requires reduction to 5 mg once daily if CrCl <30 mL/min; upadacitinib requires no adjustment 5

Clinical Decision Algorithm

Choose Upadacitinib when:

• Seeking maximum efficacy for ACR responses and clinical remission
• Rapid symptom control is priority (faster ultrasound improvement)
• Patient has renal impairment (no dose adjustment needed)
• Monotherapy is preferred or necessary

Choose Tofacitinib when:

• Cost is prohibitive (upadacitinib exceeds $60,000 annually uninsured) 7
• Patient is ≥65 years with cardiovascular risk factors AND biologics remain an option 4
• Longer real-world safety track record is valued (tofacitinib approved earlier)

Avoid both agents when:

• Active severe infections present
• Uncontrolled malignancy or recent malignancy (<5 years in most trials) 5
• Severe hepatic impairment (Child-Pugh C) 5

Special Populations

After Biologic Failure

The SELECT-CHOICE study demonstrated upadacitinib superiority over abatacept in patients with prior biologic failure 4. Post-hoc analysis of SELECT-COMPARE showed patients switched from adalimumab to upadacitinib had better outcomes than the reverse 4. This supports preferring upadacitinib in the bDMARD-inadequate responder population.

Interstitial Lung Disease

While both are JAK inhibitors, guidelines recommend avoiding TNF inhibitors in RA-ILD 4. Neither upadacitinib nor tofacitinib has specific contraindications for ILD, making them reasonable options, though long-term safety data remain limited.

Monitoring Requirements

Both require:

• Baseline and periodic CBC, liver enzymes, lipid panels
• Tuberculosis screening before initiation 5
• Herpes zoster vaccination consideration (particularly relevant in Asian populations with upadacitinib) 7

The 2-year real-world retention rate for JAK inhibitors is 78%, with insufficient effectiveness (6.5/100 person-years) being the most common discontinuation reason, followed by adverse events (4.2/100 person-years) 6.